Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
Autologous stem cell transplantation (ASCT) is one of the standard treatments of choice for eligible multiple myeloma (MM) patients. Herein, we aimed to analyze MM patients at our center and compare the clinical outcomes of single and double ASCT patients.
Guardado en:
Autores principales: | Malkan Umit Yavuz, Demiroglu Haluk, Buyukasik Yahya, Karatas Ayse, Aladag Elifcan, Goker Hakan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3f4e7162eaef4944881f5bd1d9ff437b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
por: Nikita E. Mochkin, et al.
Publicado: (2020) -
Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes
por: Peña,Camila, et al.
Publicado: (2018) -
Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
por: Jianhua Du, et al.
Publicado: (2021) -
Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
por: Fei Gao, et al.
Publicado: (2021) -
Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis
por: Mohammadi R, et al.
Publicado: (2021)